Special Issue

Pharmaceuticals for Inflammatory Bowel Disease (IBD)

Message from the Guest Editor

Inflammatory bowel disease (IBD) is a chronic and debilitating inflammation of the gastrointestinal tract. It comprises Crohn's and Ulcerative Colitis. IBD affects industrialized countries. The causes of IBD are not well established. However, its pathogenesis has been linked to genetics, microbiome, environment, and lifestyle. The clinical symptoms include loss of appetite, weight loss. severe abdominal cramps, constant diarrhea, and rectal bleeding. There is no cure for IBD, and the existing treatments, which are used for the induction and maintenance of IBD remission, are expensive and come with unwanted side effects. As a result, this comes with huge social, economic, and health burdens for people and countries. In their desperate searches for a cure, patients with IBD have been using herbal medicines, helminth therapy, and fecal microbiota transplant with limited success. There is a need for novel and effective treatments. Treatments can be developed from natural products or synthetically in laboratories. This Special Issue is dedicated to bringing in treatment perspectives from IBD clinicians, researchers, and patients.

Guest Editor

Dr. Phurpa Wangchuk

College of Public Health, Medical, and Veterinary Sciences (CPHMVS), Cairns Campus, James Cook University, Cairns, QLD 4878, Australia

Deadline for manuscript submissions

closed (31 October 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/215601

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

